California Immunology Research Bond Proposition

According to the latest prediction market data for the query “California Immunology Research Bond Proposition”, traders have formed a strong consensus.

Currently, No is dominating the market with an overwhelming 5,350% chance of winning. Yes follows in second place at 4,650%. The betting volume for this specific market has already reached —, reflecting intense industry interest.

To better assess where each potential outcome stands, the market can be segmented into three distinct trading tiers based on implied probability and contract pricing:

🥇 Tier 1: The Dominant Leader

• No (5,350%): Currently commanding the highest probability, No is heavily favored by the order book. Traders looking to back this outcome face a “Buy Yes” contract price of 5,350¢, signaling a high degree of market conviction.

🥈 Tier 2: The Primary Challengers

• Yes (4,650%): Positioned as the most viable alternative, Yes maintains a 4,650% chance of resolving true. Its “Buy Yes” shares currently trade at 4,650¢.

Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.

This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”

If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.

This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).